Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of YAP1-inhibition in Surgical Wounds.
Sponsor: Jöri Pünchera
Summary
When we get injured, our body naturally tries to heal. In adults, this healing often leads to scars - thick, stiff tissue known as fibrotic tissue. Unlike normal tissue, fibrotic tissue doesn't function properly and can cause serious health problems, depending on the affected organ. Once it forms, fibrosis is usually permanent. A good example of the fibrosis process is the healing of our skin: after a cut or surgery, the resulting scar is a type of fibrosis. Special cells called fibroblasts are key players in this process. Our study looks at a drug called verteporfin, which is already approved both in Europe and the U.S. Previous research on mice and human cells suggests it can reduce or even prevent fibrosis. We are now testing, clinically, histologically and by scRNA-seq, whether injecting verteporfin into the skin during wound healing, specifically after surgical procedures, can prevent thick, rigid scars from forming. Since the skin is easy to observe and sample, it offers a great model for studying this. Will verteporfin have an impact on how surgical wounds heal? That's what we aim to find out.
Official title: The Role of YAP1 in Fibrosis Explored Through Its Local Inhibition With Verteporfin in Surgical Wounds: A Randomized Controlled, Prospective, Evaluator-blinded Proof-of-concept Study.
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2025-05-08
Completion Date
2026-07-31
Last Updated
2025-04-25
Healthy Volunteers
No
Conditions
Interventions
NaCl (placebo)
During the safety margin excision, the placebo (NaCl) will be injected into the wound before suturing.
Verteporfin Injection
During the safety margin excision, the study drug (Verteporfin) will be injected into the wound before suturing.